Anti-angiogenic therapy has become an important component in the treatment of many solid
tumors given the importance of adequate blood supply for tumor growth and metastasis.
Despite promising preclinical data and early clinical trials, anti-angiogenic agents have
failed to show a survival benefit in randomized controlled trials of patients with glioblastoma.
In particular, agents targeting vascular endothelial growth factor (VEGF) appear to prolong
progression free survival, possibly improve quality of life, and decrease steroid usage, yet …